Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

Help

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Grocery
Pharmacy
  • Offers
  • Food Aid
  • Common Conditions 
  • Vitamins & Supplements
  • Personal Care 
  • Hygiene
  • Beauty & Health 
  • Baby Care 

    Nebicard Tablet 5mg

    10 tablets
    ৳120
    0
    in bag

    Product Information

    NEBICARD

    NEBICARD®

    Nebivolol

    Presentation

    Nebicard 2.5 tablet: Pink, round tablet. Each tablet contains Nebivolol Hydrochloride INN equivalent to Nebivolol 2.5mg. Nebicard

    5 Tablet: Pink, shield shaped tablet, scored on one side. Each tablet contains Nebivolol Hydrochloride INN equivalent to Nebivolol

    5mg.

    Nebicard Prescribing Information

    Nebivolol is a ß adrenergic receptor blocking agent. Nebivolol inhibits both ß1 and ß2-adrenergic receptors. Nebivolol lacks

    intrinsic sympathomimetic and membrane stabilizing activity at therapeutically relevant concentrations. At clinically relevant

    doses, Nebicard does not demonstrate ß1-adrenergic receptor blockade activity. Various metabolites, including glucuronides,

    contribute to beta-blocking activity.

    Pharmacodynamics

    Mode of Action of Nebicard involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of

    tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of resin activity and (5) vasodilation

    and decreased peripheral vascular resistance.

    Pharmacokinetics

    Nebivolol is metabolized by a number of routes, including glucuronidation and hydroxylation by CYP2D6. The active isomer

    (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor

    metabolizers and exposure to d-nebivolol is substantially increased in poor metabolizers. This has less importance than usual,

    however, because the metabolites, including the hydroxyl metabolite and glucuronides (the predominant circulating metabolites),

    contribute to b blocking activity.

    Absorption and Distribution

    Absorption of Nebicard is similar to an oral solution. Mean peak plasma nebivolol concentrations occur approximately 1.5 to 4

    hours post-dosing in EMs and PMs. Food does not alter the pharmacokinetics of nebivolol. Nebicard may be administered without

    regard to meals. The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is

    independent of nebivolol concentrations.

    Metabolism and Excretion

    Nebivolol is predominantly metabolized via direct glucuronidation of parent and to a lesser extent via N-dealkylation and

    oxidation via cytochrome P450 2D6. After a single oral administration of 14C-nebivolol, 38% of the dose was recovered in urine and

    44% in feces for EMs and 67% in urine and 13% in feces for PMs.

    Digoxin: Concomitant administration of Nebicard (10 mg once daily) and digoxin (0.25 mg once daily) for 10 days in 14 healthy

    adult individuals resulted in no significant changes in the pharmacokinetics of digoxin or nebivolol. Warfarin: Administration of

    Nebicard (10 mg once daily for 10 days) led to no significant changes in the pharmacokinetics of nebivolol or R- or S-warfarin

    following a single 10 mg dose of warfarin. Similarly, nebivolol has no significant effects on the anticoagulant activity of

    warfarin, as assessed by Prothrombin time and INR profiles from 0 to 144 hours after a single 10 mg warfarin dose in 12 healthy

    adult volunteers. The starting dose should be reduced in patients with moderate hepatic impairment. No formal studies have been

    performed in patients with severe hepatic impairment and nebivolol should be contraindicated for these patients.

    Indications and Usage for Nebicard

    Hypertension

    Treatment of essential hypertension.

    Chronic heart failure (CHF)

    Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients.

    Contraindications

    Nebicard is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock,

    decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), or severe hepatic impairment

    (Child-Pugh >B), and in patients who are hypersensitive to any component of this product. Warnings

    Abrupt Cessation of Therapy

    Patients with coronary artery disease treated with Nebicard should be advised against abrupt discontinuation of therapy. Severe

    exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in patients with

    coronary artery disease following the abrupt discontinuation of therapy with b-blockers. Myocardial infarction and ventricular

    arrhythmias may occur with or without preceding exacerbation of the angina pectoris. Even patients without overt coronary artery

    disease should be cautioned against interruption or abrupt discontinuation of therapy. As with other ß-blockers, when

    discontinuation of Nebicard is planned, patients should be carefully observed and advised to minimize physical activity. Nebicard

    should be tapered over 1 to 2 weeks when possible. If the angina worsens or acute coronary insufficiency develops, it is

    recommended that Nebicard be promptly reinstituted, at least temporarily.

    Cardiac Failure

    Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and

    ß-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In patients who have

    compensated congestive heart failure, Nebicard should be administered cautiously. If heart failure worsens, discontinuation of

    Nebicard should be considered.

    Angina and Acute Myocardial Infarction

    Nebicard was not studied in patients with angina pectoris or who had a recent MI.

    Bronchospastic Diseases

    In general, patients with bronchospastc diseases should not receive ß-blockers.

    Anesthesia and Major Surgery

    If Nebicard is to be continued perioperatively, patients should be closely monitored when anesthetic agents which depress

    myocardial function, such as ether, cyclopropane, and trichloroethylene, are used. If ß-blocking therapy is withdrawn prior to

    major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general

    anesthesia and surgical procedures.

    The ß-blocking effects of Nebicard can be reversed by ß-agonists, e.g., dobutamine or isoproterenol. However, such patients may be

    subject to protracted severe hypotension. Additionally, difficulty in restarting and maintaining the heartbeat has been reported

    with ß-blockers.

    Diabetes and Hypoglycemia

    ß-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective ß-blockers may potentiate

    insulin-induced hypoglycemia and delay recovery of serum glucose levels. It is not known whether nebivolol has these effects.

    Patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be

    advised about these possibilities and nebivolol should be used with caution.

    Thyrotoxicosis

    ß-blockers may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of ß-blockers may be followed by an

    exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm.

    Peripheral Vascular Disease

    ß-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution

    should be exercised in these patients.

    Non-dihydropyridine Calcium Channel Blockers

    Because of significant negative inotropic and chronotropic effects in patients treated with ß-blockers and calcium channel

    blockers of the verapamil and diltiazem type, caution should be used in patients treated concomitantly with these agents and ECG

    and blood pressure should be monitored.

    Precautions

    Impaired Renal Function

    Nebicard should be used with caution in patients with severe renal impairment because of decreased renal clearance. Nebicard has

    not been studied in patients receiving dialysis.

    Impaired Hepatic Function

    Nebicard should be used with caution in patients with moderate hepatic impairment because of decreased metabolism. Since Nebicard

    has not been studied in patients with severe hepatic impairment, Nebicard is contraindicated in this population.

    Risk of Anaphylactic Reactions

    While taking ß-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive

    to repeated challenge either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of

    epinephrine used to treat allergic reactions.

    Drug Interactions

    Nebicard should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists

    (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazerm] classes), or antiarrhythmic agents, such as

    disopyramide, are used concurrently. Both digitalis glycosides and ß-blockers slow atrioventricular conduction and decrease heart

    rate. Concomitant use can increase the risk of bradycardia.

    Nebicard should not be combined with other ß-blockers. Patients receiving catecholamine-depleting drugs, such as reserpine or

    guanethidine, should be closely monitored, because the added ß-blocking action of Nebicard may produce excessive reduction of

    sympathetic activity. In patients who are receiving Nebicard and clonidine, Nebicard should be discontinued for several days

    before the gradual tapering of clonidine.

    CYP2D6 Inhibitors: Use caution when Nebicard is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine,

    paroxetine, etc.)

    Adverse Reactions

    Headache, nausea and bradycardia.

    Nebicard Dosage and Administration

    The dose of Nebicard should be individualized to the needs of the patient. For most patients, the recommended starting dose is 5

    mg once daily, with or without food, as monotherapy or in combination with other agents. For patients requiring further reduction

    in blood pressure, the dose can be increased at 2-week intervals up to 40 mg. A more frequent dosing regimen is unlikely to be

    beneficial.

    Packaging quantites

    Nebicard 2.5 tablet: Carton containing 30 tablet in Alu-Alu blister pack.

    Nebicard 5 Tablet: Carton containing 30 tablet in Alu-Alu blister pack.

    Manufactured by

    UniMed & UniHealth Manufacturers Ltd. B. K. Bari, Gazipur, Bangladesh

    ® Registered Trademark

    Claim your 3% Discount

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna, Sylhet, Gazipur, Rajshahi and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]